Biocartesian GTM brain

category

market profile

• text: Drug discovery teams need to connect genetic perturbations with rich cellular phenotypes at scale.
• text: Pooled sequencing screens and arrayed imaging screens present different tradeoffs between throughput and phenotypic detail.

personas

• title: Director of functional genomics
  pains:

  • Pooled screens miss complex morphology or localization phenotypes
  • Arrayed screens are costly and difficult to scale across perturbations
• title: Drug discovery program lead
  pains:

  • Needs evidence linking candidate genes to disease-relevant cellular effects
  • Mechanism-of-action and target prioritization demand richer readouts
• title: High-content screening scientist
  pains:

  • Must connect images to the perturbation in each cell
  • Limited automation or assay capacity constrains screen design

icp

• text: Biotech and pharmaceutical research groups running CRISPR target discovery or mechanism-of-action studies.
• text: Research teams with relevant cell models, microscopy assays or pooled libraries that need image-linked perturbation readouts.
• text: Teams choosing between outsourced full-service screening and performing cell culture or readout work in-house.

message pillars

• text: Link perturbations to rich single-cell imaging.
• text: Combine large pooled libraries and microscopy readouts.
• text: Choose a service scope that fits internal capabilities.

objections

• objection: Will the assay work in our cell model and with our phenotype?
  response: Scope a representative feasibility experiment and agree readout and quality criteria with the scientific team.
• objection: Must we outsource the entire experiment?
  response: The site describes full-service, cell-culture-in-house and readout-only project options.
• objection: How does this compare to an established pooled or arrayed screen?
  response: Compare cost, throughput and phenotype information on the intended biological question, not just perturbation count.

competitors

• name: Bifrost Biosystems
  website: https://bifrost.bio/technology/
  why: Offers microscopy-based genome-wide pooled CRISPR screening.
• name: Cellecta
  website: https://cellecta.com/products/crispr-rnai-screening-services
  why: Provides pooled genetic screening services for target discovery and mechanisms.
• name: Revvity
  website: https://www.revvity.com/category/functional-genomic-screening-services
  why: Offers pooled and arrayed functional genomic screening services.

keywords

• optical pooled screening
• image based CRISPR screen
• functional genomics screening service
• cell painting pooled screen
• single cell perturbation imaging
• drug target discovery screen
• mechanism of action screening

voice

• Scientific and precise
• Application-focused
• Collaborative

signals

• text: A discovery team is launching a CRISPR screen requiring morphological or spatial phenotypes.
• text: A lab is scaling high-content screens but finds arrayed workflows too expensive or difficult to automate.

pricing

motion

channels

• SEO
• LinkedIn
• YC directory

confidence

Founders

• name: Ian Dardani
  title: Founder/CEO
  role: CEO
  bio: Co-founder of Biocartesian. Microscopy + molecular tools + engineering. Previously Bioscience Enterprise at Cambridge, Bioengineering PhD at UPenn.
• name: Jess Li
  title: Founder
  role: Founder
  bio: Co-founder of Biocartesian. Genetics + epigenetics, next-gen sequencing. Previously PhD at UPenn, BD at imvaria.